GNPX · Genprex, Inc. · Documents
$1.81
-0.17 (-8.59%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result of our recurring losses from operations and the need for additional financing to fund our operating and capital requirements, there is uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively over the next 12 months, which raises substantial doubt as to our ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$1.62M
Shares
819,709
Volume · Oct 23
210.77K
Avg daily vol (3M)
273.26K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | Genprex highlighted peer-reviewed mouse research suggesting TUSC2 supports healthy brain aging; TUSC2 expression declined significantly with age in 11 of 13 examined human brain regions. | 2026-10-21 | — | |
| 8-K | — | 2026-08-18 | — | |
| 10-Q | — | 2026-08-14 | 2026-06-30 | |
| 8-K | — | 2026-08-05 | 2026-08-04 | |
| 8-K | — | 2026-08-03 | — | |
| 8-K | — | 2026-07-30 | 2026-07-29 | |
| 8-K | — | 2026-07-14 | 2026-07-13 | |
| 8-K | — | 2026-06-22 | — | |
| 8-K | — | 2026-06-18 | — | |
| 8-K | — | 2026-06-12 | 2026-06-10 | |
| S-3 | — | 2026-06-05 | — | |
| 8-K | — | 2026-05-26 | — | |
| 8-K | — | 2026-05-14 | — | |
| 10-Q | — | 2026-05-13 | 2026-03-31 | |
| 8-K | — | 2026-04-30 | — | |
| DEF 14A | — | 2026-04-29 | 2026-06-18 | |
| ARS | — | 2026-04-29 | 2025-12-31 | |
| 8-K | — | 2026-04-28 | — | |
| 8-K | — | 2026-04-21 | — | |
| PRE 14A | — | 2026-04-17 | 2026-06-18 | |
| 10-K | — | 2026-03-30 | 2025-12-31 | |
| 8-K | — | 2026-03-18 | — | |
| 8-K | — | 2026-02-23 | — | |
| 8-K | — | 2026-02-10 | — | |
| 8-K | — | 2026-01-09 | 2026-01-07 | |
| 8-K | — | 2026-01-07 | — | |
| 8-K | — | 2026-01-06 | — | |
| 8-K | — | 2025-12-23 | — | |
| 8-K | — | 2025-11-26 | 2025-11-25 | |
| S-1/A | — | 2025-11-26 | — | |
| S-1 | — | 2025-11-21 | — | |
| 8-K | — | 2025-11-21 | — | |
| 8-K | — | 2025-11-19 | — | |
| 8-K | — | 2025-11-18 | — | |
| 10-Q | — | 2025-11-14 | 2025-09-30 | |
| 8-K | — | 2025-11-04 | — | |
| 8-K | — | 2025-10-29 | 2025-10-28 | |
| 8-K | — | 2025-10-28 | — | |
| 8-K | — | 2025-10-24 | 2025-10-23 | |
| 8-K | — | 2025-10-23 | — | |
| 8-K | — | 2025-10-21 | — | |
| 8-K | — | 2025-10-17 | 2025-10-13 | |
| S-1 | — | 2025-09-12 | — | |
| 8-K | — | 2025-08-20 | 2025-08-19 | |
| 8-K | — | 2025-08-18 | — | |
| 8-K | — | 2025-08-15 | — | |
| 10-Q | — | 2025-08-14 | 2025-06-30 | |
| DEFA14A | — | 2025-08-04 | — | |
| 8-K | — | 2025-08-04 | — | |
| ARS | — | 2025-07-16 | 2024-12-31 |
Showing 1–50 of 204 filings